No Data
No Data
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference
HC Wainwright & Co. Reiterates Buy on Equillium, Maintains $5 Price Target
Equillium Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Equillium (EQ), Foghorn Therapeutics (FHTX) and Immix Biopharma, Inc. (IMMX)
H.C. Wainwright Maintains Equillium(EQ.US) With Buy Rating, Maintains Target Price $5
H.C. Wainwright analyst Ram Selvaraju maintains $Equillium(EQ.US)$ with a buy rating, and maintains the target price at $5.According to TipRanks data, the analyst has a success rate of 42.2% and a